Navigation Links
Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Date:1/17/2012

HOBOKEN, N.J. and PHILADELPHIA, Jan. 17, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor.

The NKP-1339 single agent dose escalation Phase I trial was conducted in patients with advanced solid tumors resistant to multiple, standard therapies. NKP-1339 was administered intravenously once weekly for 3 weeks followed by one week of no treatment. Thirty-four patients were treated, of which 30 were evaluable for dose determination. The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare in partnership with Translational Genomics Institute, and Dr. Howard Burris, at the Sarah Cannon Research Institute.

The NKP-1339 dose limiting toxicity was grade 2-3 nausea and grade 1-2 reversible renal insufficiency. At the recommended Phase II dose, NKP-1339 treatment was generally well tolerated and had manageable side effects. The most common drug-related side effects were grade 1 nausea, grade 1-2 vomiting and grade 1-2 fatigue. Infusional fever and chills were noted but prevented with steroid premedication.

"We reached our goal to determine the dose of NKP-1339 to take forward in future trials. Many toxicities commonly associated with other anticancer drugs, such as neutropenia, hepatotoxicity, neuropathy, rash, mucositis, diarrhea and alopecia, have not been seen to date," said Dr. Burris.

Anti-tumor activity, demonstrated by disease stability and/or tumor regression for 12-88+ weeks, was noted in patients with neuroendocrine tumors (NET), non-small cell lung cancer, sarcoma, colorectal and cancer of unknown primary. Three patients continue to receive NKP-1339 therapy on study.

"The preliminary read of NKP-1339 anti-tumor activity
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
2. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
3. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... PharmaPoint: Type 1 Diabetes - Global Drug Forecast ... diabetes (T1D) is an autoimmune disease that permanently destroys beta ... can no longer produce insulin. Over the last 90 years, ... other treatment can be offered to a patient who is ... different times of action - long-acting as well as short ...
(Date:5/27/2015)... NEW YORK , May 27, 2015  Precision ... announced the findings from its 2015 Digital Trends Study ... decision makers are aware of the concepts of big ... fully implement them.  The Health Information ... incentives for healthcare providers to make use of electronic ...
(Date:5/27/2015)... , May 27, 2015  LumiThera Inc., ... non-invasive photobiomodulation (PBM) treatment for ocular disorders and ... Washington State Life Sciences ... 3 recipients of the LSDF matching grants worth ... treatment for subjects with dry age-related macular degeneration ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... , LAVAL, QC, Aug. 5 /PRNewswire-FirstCall/ - Labopharm Inc. ... it has filed a New Drug Submission (NDS) with ... novel formulation of the antidepressant trazodone. , "We are ... Canada," said James R. Howard-Tripp, President and Chief Executive ...
... WORTH, Texas, Aug. 4 Of the 600,000-800,000 people trafficked across international ... by 2010, human trafficking will be the No. 1 crime worldwide. ... chairman of the department of forensic and investigative Genetics and co-director of ... University of North Texas (UNT) Health Science Center , ...
Cached Medicine Technology:Labopharm files New Drug Submission with Health Canada for novel antidepressant 2Labopharm files New Drug Submission with Health Canada for novel antidepressant 3DNA Helps Reunite Children With Their Families 2DNA Helps Reunite Children With Their Families 3
(Date:5/27/2015)... The BBB Code of Business Practices ... enhance customer trust and confidence in business. The Code ... principles that summarize important elements of creating and maintaining ... business accreditation by BBB. Businesses based in the United ... application procedures will be accredited by BBB. , To ...
(Date:5/27/2015)... Continuing its commitment to finding a cure ... community, SmartPractice® donated $25,000 to HonorHealth Breast ... Vice President of Human Resources Meg Mosher and SmartScrubs ... to Paulla Miller, Sherry Gage, Dr. Linda Greer and ... on April 30. The center is located at 19646 ...
(Date:5/27/2015)... Allred Dental located in San Marcos, CA ... need extensive dental treatment - understand the oral issues they ... their problems. , Dr. Jeff Allred calls it “Dental Case ... assessment of the patient’s oral health and problems together with ... oral health problems. , “The dental case planning process starts ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Black ... customer satisfaction surveys in the multiple services and ... to determine the highest ranked Electronic Health and ... of a special research focus on implemented EHR ... those software vendors with the highest scores in ...
(Date:5/27/2015)... May 27, 2015 The MedSpa at ... FDA-approved dermal filler treatments in Abilene, Texas: Xeomin®, Belotero ... the appearance of glabellar lines, better known as the ... Balance® is designed to treat smoker’s lines around the ... chin, while Radiesse® improves the appearance of smile lines ...
Breaking Medicine News(10 mins):Health News:Carson Energy Receives A+ Accredited Rating For 19 Consecutive Years 2Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:San Marcos Dentistry Office Offering a New Service Dental Case Planning 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... , FRIDAY, Aug. 5 (HealthDay News) -- Smoking ... atrial fibrillation, a new study warns. U.S. researchers reviewed ... who were followed for an average of 13 years, and ... time. The risk of the abnormal heart rhythm was ...
... (HealthDay News) -- Children with HIV who receive antiretroviral ... (lipid) levels, and would benefit from guidelines aimed at ... findings are published in JAIDS: Journal of Acquired ... first crucial step in minimizing cardiovascular disease complications and ...
... in Spanish . , ANN ARBOR, Mich. ... be used safely and effectively even in tumors from the ... the University of Michigan Comprehensive Cancer Center. Sentinel lymph ... first node where cancer would likely spread. If that node ...
... --,Smokers who take a multivitamin pill may think they can ... affects of cigarettes, according to a new study. Researchers ... will reduce their risk of cancer, allowing them to light ... a virtuous behavior for a subsequent indulgence, known as the ...
... WHAT: Scientists from around the world will gather ... order to improve health through advances in pharmaceutical sciences ... In recognition of AAPS,s 25th anniversary, this year,s meeting, ... sessions, including more than 60 symposia and roundtables. ...
... , THURSDAY, Aug. 4 (HealthDay News) -- American military veterans ... suicide than fellow students who have never been in the ... poll paints a grave picture of these students, mental health: ... they have considered suicide at some point in their lives, ...
Cached Medicine News:Health News:Children's HIV Drugs May Cause High Cholesterol 2Health News:Sentinel node biopsy safe, effective in head and neck melanomas, U-M study finds 2Health News:Smokers Mistakenly Believe Vitamins Protect Them From Cancer 2Health News:Many Military Vets in College Plagued By Thoughts of Suicide 2Health News:Many Military Vets in College Plagued By Thoughts of Suicide 3
... 6-Place Rotor has a standard 1.5ml rotor and ... adapters. Easy operation (no switches to mess with). ... press the plastic tab to open. Starts and ... and 2000 x g. Only five inches in ...
... which allows user to stop rotor before opening ... stainless steel pin is virtually indestructible. Lid release ... microcentrifuge tubes at low to medium speed (up ... inch x 6 inch footprint. Starts and stops ...
Inquire...
Inquire...
Medicine Products: